Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats.
- 1998-02-01
- Carcinogenesis 19(2)
- I. Rowland
- C. Rumney
- J. Coutts
- L. Lievense
- PubMed: 9498277
- DOI: 10.1093/CARCIN/19.2.281
Abstract
The effect of Bifidobacterium longum (4 x 10(8) viable cells/g diet) and a derivative of inulin ('Raftiline HP'; 5% w/w in diet) on colonic aberrant crypt foci (ACF) induced by the colon carcinogen azoxymethane (AOM) has been studied. The concentration of ammonia, a putative tumour promoter produced by bacterial degradation of protein and urea, and the activities of certain bacterial enzymes thought to play a role in colon carcinogenesis, beta-glucuronidase and beta-glucosidase were also assayed. Consumption of either B. longum or inulin was associated with a decrease (26 and 41%, respectively) in AOM-induced small ACF (i.e. those comprising 1-3 aberrant crypts per focus). Combined administration of the bifidobacterium and inulin resulted in more potent inhibition of ACF than administration of the two separately, achieving 80% inhibition of small ACF. Furthermore, the combined administration significantly decreased the incidence (by 59%) of large ACF (>4 aberrant crypts per focus), which are considered to be predictive of eventual tumour incidence. Since the dietary treatments were started 1 week after the carcinogen dose, the results suggest that B. longum and inulin may be affecting the early promotion phase of the carcinogenic process. Consumption of diets containing B. longum, inulin or both were also associated with decreases in beta-glucuronidase activity and ammonia concentration in the caecal contents. Both these factors have been associated with carcinogenesis of the colon in experimental animal models. In rats given inulin-containing diets (with or without B. longum) an increase in caecal wt and beta-glucosidase activity and a decrease in caecal pH were observed. The results suggest that consumption of B. longum or inulin was associated with potentially beneficial changes in caecal physiology and bacterial metabolic activity in relation to tumour risk and in the incidence of putative preneoplastic lesions in the colon. The results also indicated that combined treatment with the two agents was more effective in reducing colonic lesions.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bifidobacterium longum B1-05 | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum B1-05 | Reduced Caecal Ammonia Concentration | Beneficial | Large |
Bifidobacterium longum B1-05 | Reduced Cecal pH Levels | Neutral | Small |
Bifidobacterium longum B1-05 | Reduced Colonic Aberrant Crypt Foci | Beneficial | Moderate |
Bifidobacterium longum BI-05 | Reduced Aberrant Crypt Foci Incidence | Beneficial | Large |
Bifidobacterium longum BI-05 | Reduced Enzyme Activity | Beneficial | Moderate |
Bifidobacterium longum BL03 | Reduced Aberrant Crypt Foci | Beneficial | Moderate |
Bifidobacterium longum BL03 | Reduced Ammonia Concentration | Beneficial | Moderate |
Bifidobacterium longum BL03 | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum BL03 | Reduced Carcinogen-Induced Large Aberrant Crypt Foci (ACF) | Beneficial | Large |
Bifidobacterium longum BL03 | Reduced Tumor Risk | Beneficial | Moderate |
Bifidobacterium longum HA-135 | Reduced Ammonia Concentration | Beneficial | Moderate |
Bifidobacterium longum HA-135 | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum HA-135 | Reduced Cecal pH Levels | Neutral | Small |
Bifidobacterium longum HA-135 | Reduced Colonic Aberrant Crypt Foci | Beneficial | Moderate |
Bifidobacterium longum HA-135 | Reduced Incidence of Large Aberrant Crypt Foci | Beneficial | Large |
Bifidobacterium longum iVE-15 | Reduced Aberrant Crypt Foci Formation with Combined Administration | Beneficial | Large |
Bifidobacterium longum iVE-15 | Reduced Aberrant Crypt Foci Induced by Azoxymethane | Beneficial | Moderate |
Bifidobacterium longum iVE-15 | Reduced Incidence of Large ACF | Beneficial | Moderate |
Bifidobacterium longum KABP-042 | Increased Caecal Weight | Neutral | Small |
Bifidobacterium longum KABP-042 | Reduced Aberrant Crypt Foci Incidence | Beneficial | Large |
Bifidobacterium longum KABP-042 | Reduced Ammonia Concentration | Beneficial | Moderate |
Bifidobacterium longum KABP-042 | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum KABP-042 | Reduced Cecal pH Levels | Neutral | Small |
Bifidobacterium longum MAK34B12L | Reduced AOM-Induced Small Colonic Aberrant Crypt Foci | Beneficial | Moderate |
Bifidobacterium longum MAK34B12L | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum MAK34B12L | Reduced Caecal Ammonia Concentration | Beneficial | Large |
Bifidobacterium longum MAK34B12L | Reduced Cecal pH Levels | Neutral | Small |
Bifidobacterium longum MAK34B12L | Reduced Incidence of Large Colonic Aberrant Crypt Foci (ACF) | Beneficial | Large |
Bifidobacterium longum MM-2 | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum MM-2 | Reduced Caecal Ammonia Concentration | Beneficial | Large |
Bifidobacterium longum MM-2 | Reduced Colonic Aberrant Crypt Foci | Beneficial | Moderate |
Bifidobacterium longum MM-2 | Reduced Large Colonic Aberrant Crypt Foci | Beneficial | Moderate |
Bifidobacterium longum Rosell-175 | Increased Beta-Glucosidase Activity | Neutral | Small |
Bifidobacterium longum Rosell-175 | Reduced Aberrant Crypt Foci | Beneficial | Moderate |
Bifidobacterium longum Rosell-175 | Reduced Ammonia Concentration | Beneficial | Moderate |
Bifidobacterium longum Rosell-175 | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum Rosell-175 | Reduced Cecal pH Levels | Neutral | Small |
Bifidobacterium longum SD-5588 | Increased Beta-Glucosidase Activity | Neutral | Small |
Bifidobacterium longum SD-5588 | Increased Caecal Weight | Neutral | Small |
Bifidobacterium longum SD-5588 | Reduced Aberrant Crypt Foci Induced by Azoxymethane | Beneficial | Moderate |
Bifidobacterium longum SD-5588 | Reduced Ammonia Concentration | Beneficial | Moderate |
Bifidobacterium longum SD-5588 | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum SD-5588 | Reduced Cecal pH Levels | Neutral | Small |
Bifidobacterium longum SD-5588 | Reduced Incidence of Large Aberrant Crypt Foci | Beneficial | Large |
Bifidobacterium longum SP54 | Reduced AOM-Induced Small Aberrant Crypt Foci (Combined Administration) | Beneficial | Large |
Bifidobacterium longum SP54 | Reduced Aberrant Crypt Foci Induced by Azoxymethane | Beneficial | Moderate |
Bifidobacterium longum SP54 | Reduced Incidence of Large Aberrant Crypt Foci (ACF) | Beneficial | Moderate |
Bifidobacterium longum subsp. longum | Increased Beta-Glucosidase Activity | Neutral | Small |
Bifidobacterium longum subsp. longum | Reduced Ammonia Concentration | Beneficial | Moderate |
Bifidobacterium longum subsp. longum | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum subsp. longum | Reduced Cecal pH Levels | Neutral | Small |
Bifidobacterium longum subsp. longum | Reduced Large Aberrant Crypt Foci | Beneficial | Large |
Bifidobacterium longum subsp. longum | Reduced Small Aberrant Crypt Foci | Beneficial | Moderate |
Bifidobacterium longum subsp. longum UABI-14 | Increased Beta-Glucosidase Activity | Neutral | Small |
Bifidobacterium longum subsp. longum UABI-14 | Increased Caecal Weight | Neutral | Small |
Bifidobacterium longum subsp. longum UABI-14 | Reduced Aberrant Crypt Foci | Beneficial | Moderate |
Bifidobacterium longum subsp. longum UABI-14 | Reduced Ammonia Levels | Beneficial | Moderate |
Bifidobacterium longum subsp. longum UABI-14 | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum subsp. longum UABI-14 | Reduced Cecal pH Levels | Neutral | Small |
Bifidobacterium longum subsp. longum UABI-14 | Reduced Incidence of Large Aberrant Crypt Foci | Beneficial | Large |
Bifidobacterium longum UABI-14 | Reduced Aberrant Crypt Foci Induced by Azoxymethane | Beneficial | Moderate |
Bifidobacterium longum UABI-14 | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum UABI-14 | Reduced Caecal Ammonia Concentration | Beneficial | Large |
Bifidobacterium longum UABI-14 | Reduced Large Aberrant Crypt Foci | Beneficial | Large |
Bifidobacterium longum UABl-14 | Increased Beta-Glucosidase Activity | Neutral | Small |
Bifidobacterium longum UABl-14 | Reduced Aberrant Crypt Foci | Beneficial | Moderate |
Bifidobacterium longum UABl-14 | Reduced Ammonia Concentration | Beneficial | Moderate |
Bifidobacterium longum UABl-14 | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Bifidobacterium longum UABl-14 | Reduced Cecal pH Levels | Neutral | Small |
Bifidobacterium longum UABl-14 | Reduced Incidence of Large Aberrant Crypt Foci | Beneficial | Large |